David Margolin - Concepedia

Author

David Margolin

Also Known As

D H Margolin, D. H. Margolin, D. Margolin, D.H. Margolin, DAVID H. MARGOLIN, David H Margolin, David H Margolin*, David H. Margolin, David Margolin, Margolin, D. H.

162

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

University of Cambridge Sanofi (United States)Cleveland Clinic Charles University Beth Israel Deaconess Medical Center

About

David Margolin is an author at University of Cambridge specializing in medicine, neuroscience, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	3K
2	Social Sciences	4	4	129
3	Public Health	1	1	11
4	Allergy	1	1	15
5	Emergency Medicine	1	1	38

David Margolin

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold, The Lancet RheumatologyRelapsing-remitting Multiple SclerosisImmunologyClinical TrialsTreatment Option	2012	1.2K
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Alasdair Coles, Cary Twyman, Douglas L. Arnold, The Lancet ImmunologyClinical TrialsNeurological ProgressDisease-modifying TherapyMultiple Sclerosis	2012	1.2K
Alemtuzumab CARE-MS II 5-year follow-up Alasdair Coles, Jeffrey Cohen, Edward Fox, Neurology	2017	273
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial Alasdair Coles, Edward Fox, Anton Vladić, Neurology	2012	260
Ataxia, Dementia, and Hypogonadotropism Caused by Disordered Ubiquitination David Margolin, Maria Kousi, Yee-Ming Chan, New England Journal of Medicine	2013	229
Alemtuzumab CARE-MS I 5-year follow-up Eva Havrdová, Douglas L. Arnold, Jeffrey Cohen, Neurology	2017	222
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity Joanne Jones, JANE ANDERSON, Chia‐Ling Phuah, Brain	2010	163
Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual Renaud Du Pasquier, Smith Corey, David Margolin, Neurology	2003	152
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis Gilbert H. Daniels, Anton Vladić, Vesna Brinar, The Journal of Clinical Endocrinology & Metabolism	2013	146
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes Alasdair Coles, Edward Fox, Anton Vladić, The Lancet Neurology RheumatologyClinical Efficacy OutcomesAutoimmune DiseaseDisease ProgressionMedicine	2011	138

Page 1